Sorrento Therapeutics Inc. [NASDAQ: SRNE] closed the trading session at $9.64 on 01/22/21. The day’s price range saw the stock hit a low of $9.39, while the highest price level was $9.969. The company report on January 20, 2021 that Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical development for treatment of patients with COVID-19 disease.
Dr. Robert Allen, Senior Vice President, Antiviral and Oncolytic Immunotherapy Development at Sorrento and Chief Scientific Officer of SmartPharm Therapeutics, will be presenting data from the SARS-CoV-2 Spike protein variant screening program at PepTalk 2021 and on Thursday of this week.
The stocks have a year to date performance of 41.25 percent and weekly performance of 20.65 percent. The stock has been moved at 23.59 percent over the last six months. The stock has performed 26.68 percent around the most recent 30 days and changed 22.80 percent over the most recent 3-months.
If compared to the average trading volume of 15.02M shares, SRNE reached to a volume of 13928444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sorrento Therapeutics Inc. [SRNE]:
Alliance Global Partners have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 21, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $24 to $30. The new note on the price target was released on July 31, 2020, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise to $24, while Dawson James analysts kept a Buy rating on SRNE stock.
The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.71, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 63.23. The Price to Book ratio for the last quarter was 11.76.
SRNE stock trade performance evaluation
Sorrento Therapeutics Inc. [SRNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.65. With this latest performance, SRNE shares gained by 26.68% in over the last four-week period, additionally plugging by 23.59% over the last 6 months – not to mention a rise of 130.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 65.36, with the RSI for the last a single of trading hit 69.48, and the three-weeks RSI is set at 61.50 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 7.58, while it was recorded at 9.72 for the last single week of trading, and 7.22 for the last 200 days.
Sorrento Therapeutics Inc. [SRNE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -620.97 and a Gross Margin at +48.53. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -929.21.
Return on Total Capital for SRNE is now -51.07, given the latest momentum, and Return on Invested Capital for the company is -76.62. Return on Equity for this stock declined to -202.78, with Return on Assets sitting at -45.19. When it comes to the capital structure of this company, Sorrento Therapeutics Inc. [SRNE] has a Total Debt to Total Equity ratio set at 370.01. Additionally, SRNE Total Debt to Total Capital is recorded at 78.72, with Total Debt to Total Assets ending up at 47.05. Long-Term Debt to Equity for the company is recorded at 319.64, with the Long-Term Debt to Total Capital now at 68.01.
Reflecting on the efficiency of the workforce at the company, Sorrento Therapeutics Inc. [SRNE] managed to generate an average of -$942,155 per employee. Receivables Turnover for the company is 3.33 with a Total Asset Turnover recorded at a value of 0.05.Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.20.
Earnings per share (EPS) analysis for Sorrento Therapeutics Inc. [SRNE] stock
With the latest financial reports released by the company, Sorrento Therapeutics Inc. posted -0.41/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.
Sorrento Therapeutics Inc. [SRNE]: Insider Ownership positions
There are presently around $695 million, or 28.00% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: BLACKROCK INC. with ownership of 15,016,558, which is approximately 19.758% of the company’s market cap and around 15.71% of the total institutional ownership; STATE STREET CORP, holding 11,708,587 shares of the stock with an approximate value of $112.87 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $107.03 million in SRNE stock with ownership of nearly 13.661% of the company’s market capitalization.
Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 140 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 16,213,217 shares. Additionally, 73 investors decreased positions by around 5,446,478 shares, while 27 investors held positions by with 50,479,736 shares. The mentioned changes placed institutional holdings at 72,139,431 shares, according to the latest SEC report filing. SRNE stock had 61 new institutional investments in for a total of 1,893,628 shares, while 32 institutional investors sold positions of 1,086,750 shares during the same period.